Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
Kei Nagao,1,2 Taro Kishi,1 Masatsugu Moriwaki,1 Kiyoshi Fujita,3,4 Shigeki Hirano,5 Yoshio Yamanouchi,1 Toshihiko Funahashi,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, The Jindai Hospital, Toyota, Aichi, Jap...
Enregistré dans:
Auteurs principaux: | Nagao K, Kishi T, Moriwaki M, Fujita K, Hirano S, Yamanouchi Y, Funahashi T, Iwata N |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/de2e1ba97dc04e0981a8943b9fdfdbc4 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study
par: Sibel Cakir, et autres
Publié: (2008) -
Identifying predictive clinical characteristics of the treatment efficacy of mirtazapine monotherapy for major depressive disorder
par: Tsutsumi T, et autres
Publié: (2016) -
Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
par: Kishi T, et autres
Publié: (2017) -
Efficacy comparison of duloxetine and SSRIs at doses approved in Japan
par: Harada E, et autres
Publié: (2015) -
Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
par: Huang J, et autres
Publié: (2018)